TY - JOUR T1 - Pulmonary arterial hypertension in patients treated with interferon JF - European Respiratory Journal JO - Eur Respir J SP - 1849 LP - 1851 DO - 10.1183/13993003.02327-2014 VL - 46 IS - 6 AU - Maura Prella AU - Patrick Yerly AU - Laurent P. Nicod AU - John-David Aubert Y1 - 2015/12/01 UR - http://erj.ersjournals.com/content/46/6/1849.abstract N2 - We read with interest the article by Savale et al. [1] reporting pulmonary arterial hypertension (PAH) associated with treatment with interferon (IFN) in 53 patients from the French PAH registry. As noted by the authors, patients receiving IFN-α have confounding factors such as portal hypertension or HIV infection that may classify them in group 1.4.3 or 1.4.2, respectively, according to the 2013 updated pulmonary hypertension classification [2]. Therefore, “pure” cases, such as those treated with IFN-β for multiple sclerosis are important to identify in order to strengthen the causal relationship between the suspected drug and PAH.Suspected drug-induced PAH cases should be reported to pharmacovigilance networks and regulatory agencies http://ow.ly/TthdY ER -